secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2026-02-04T23:59:59+00:00
Accession:  0001213900-26-012274
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals announces 1-for-25 reverse stock split to meet Nasdaq $1 minimum bid price
--------------------------------------------------------------------------------

- Reverse split reduces shares from ~27.8M to ~1.1M; effective 11:59 p.m. ET on Feb 5, 2026.
- Split-adjusted trading begins Feb 6 under symbol ADIL; new CUSIP 00688A304; cash for fractional shares.
- Goal: regain compliance with Nasdaq minimum $1 bid price; no assurance of desired effect.
- Proportional adjustments to equity awards and warrants; authorized shares unchanged.
- CEO Claiborne cites progress on AD04 for Alcohol Use Disorder and partnering strategies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026012274/0001213900-26-012274-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026012274/ea0275033-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-012274

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer